Who is sponsoring NCT02139618?

NCT02139618 is sponsored by Fundación Dermabase.

What condition does NCT02139618 study?

NCT02139618 studies Facial Photodamage.

What drugs are being tested in NCT02139618?

Interventions: Methyl Aminolevulinate (MAL), Placebo.

What is the status of NCT02139618?

NCT02139618 is currently COMPLETED.

Last reviewed 2015-03-05 · How we verify

A Double-blind Randomized-controlled Trial to Assess the Efficacy of Methyl Aminolevulinate + Daylight vs Placebo + Daylight in Patients With Facial Photodamage

NCT02139618 Phase 2 COMPLETED

Treatment of actinic damage has included multiple procedures but to date there is limited scientific evidence to support the preferential use of one of these therapies according to their efficacy, safety and pain tolerance by patients. This study aims to assess the efficacy of methyl aminolevulinate + daylight vs placebo + daylight to treat facial photodamage

Details

Lead sponsor	Fundación Dermabase
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	2014-04
Completion	2014-10

Conditions

Facial Photodamage

Interventions

Methyl Aminolevulinate (MAL)
Placebo

Primary outcomes

Global photodamage improvement — 1 month after third session
The primary outcome is global photodamage improvement 1 month after the third daylight PDT session, according to Dover´s photodamage scale.

Countries

Colombia